Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- It’s Time to Look at Supply Status, NHI-Market Price Gap to Revisit Drug Pricing: MHLW Official
April 11, 2022
- Generic Rates at Innovative Drug Makers Hovers at 60% Range: MHLW Data
April 11, 2022
- MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- Extension of Emergency Approval Period Would Be Allowed Only Once: MHLW Official
April 7, 2022
- Moderna, Daiichi Sankyo Give mRNA Vaccine Updates: LDP Meeting
April 7, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- MHLW Lays Out CDx Requirements for Use with Multiple Drugs
April 6, 2022
- Label Revisions Ordered for Somatropin, IFNβ-1a/1b Preparations
April 5, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- MHLW Presents Policy for Use of “Specified Clinical Research” Data in Regulatory Submissions
April 4, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
- Fourth COVID Shots for Older Adults and High-Risk People: LDP Project Team
April 1, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- Working Group Launched under Pharma Industry Vision Meets for 1st Time
March 31, 2022
- Vonvendi Label Revised for Routine Prophylaxis in VWD
March 30, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…